{
    "clinical_study": {
        "@rank": "157942", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra SC", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, single arm, long-term extension study will evaluate the safety\n      and efficacy of RoActemra/Actemra in patients with moderate to severe rheumatoid arthritis\n      who have completed the 97-week WA22762 core study. Patients will receive RoActemra/Actemra\n      162 mg subcutaneously weekly for 104 weeks."
        }, 
        "brief_title": "A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients who have completed the 97-week WA22762 core study on subcutaneous or\n             intravenous RoActemra/Actemra and who experienced at any time during WA22762\n             clinically significant improvement in DAS28 (>1.2 points), and based on the\n             investigator's judgment may continue to benefit from RoActemra/Actemra treatment in\n             this study investigating the subcutaneous formulation\n\n          -  No current or recent adverse events or laboratory findings preventing the use of the\n             study drug dose of RoActemra/Actemra 162 mg sc at baseline visit\n\n          -  Receiving treatment on an outpatient basis\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential must agree to use reliable means of contraception during the study and for\n             at least 3 months following the last dose of study drug\n\n          -  Oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) up to the\n             recommended dose are permitted if on stable dose regimen for >/= 4 weeks prior to\n             baseline\n\n          -  Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed\n\n        Exclusion Criteria:\n\n          -  Patients who have prematurely withdrawn from the WA22762 core study for any reason\n\n          -  Previous treatment with any cell-depleting therapies, including investigational\n             agents or approved therapies\n\n          -  Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent,\n             or a T-cell costimulation modulator since the last administration of study drug in\n             the WA22762 core study\n\n          -  Immunization with a live/attenuated vaccine since the last administration of study\n             drug in the WA22762 core study\n\n          -  Diagnosis since last WA22762 visit (Week 97) of rheumatic disease other than\n             rheumatoid arthritis; secondary Sj\u00f6rgen's syndrome with RA is permitted\n\n          -  Diagnosis since last WA22762 visit (Week 97) of inflammatory joint disease other than\n             rheumatoid arthritis\n\n          -  Uncontrolled disease states, such as asthma or inflammatory bowel disease, where\n             flares are commonly treated with oral or parenteral corticosteroids\n\n          -  Evidence of serious uncontrolled concomitant disease\n\n          -  Known active current or history of recurrent infection\n\n          -  Primary or secondary immunodeficiency (history of or currently active)\n\n          -  Body weight > 150 kg\n\n          -  Pregnant or lactating women\n\n          -  Inadequate hematologic, renal or liver function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734993", 
            "org_study_id": "ML28544"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra SC", 
            "description": "162 mg subcutaneously weekly, 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44035"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75679"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67098"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A MULTICENTER, OPEN-LABEL LONG-TERM EXTENSION STUDY OF WA22762 TO EVALUATE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in disease activity: Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) and/or Simplified Disease Activity Index (SDAI)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 104"
            }, 
            {
                "measure": "Change in total tender joint count (TJC) / swollen joint count (SJC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 104"
            }, 
            {
                "measure": "Proportion of patients with remission (DAS28 <2.6 or SDAI </=3.3) at Weeks 52 and 104", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Proportion of patients with corticosteroid dose reductions and/or discontinuation", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}